Fukuoka, Japan

Shinro Setoguchi


Average Co-Inventor Count = 3.4

ph-index = 1

Forward Citations = 28(Granted Patents)


Company Filing History:


Years Active: 1981-1993

Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovations of Shinro Setoguchi

Introduction

Shinro Setoguchi is a notable inventor based in Fukuoka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with therapeutic applications. With a total of 4 patents to his name, Setoguchi continues to push the boundaries of innovation in his industry.

Latest Patents

Among his latest patents is a thiadiazine compound featuring a novel crystalline form. This includes the development of novel .beta.-form crystals of 6-(3,6-dihydro-2-oxo-2H-1,3,4-thiadiazin-5-yl)-3,4-dihydro-2(1H)-quinolino, which is useful as cardiotonics. Additionally, he has patented processes for preparing optically active compounds. This invention provides an industrially valuable method for preparing an optically active 3,4-dihydro-3,4-epoxy-2H-1-benzopyran compound, which serves as a starting material for an optically active benzopyran compound with antihypertensive and coronary blood flow-increasing activities.

Career Highlights

Setoguchi is currently employed at Yoshitomi Pharmaceutical Industries, Ltd., where he applies his expertise in pharmaceutical innovation. His work has been instrumental in advancing the company's research and development efforts.

Collaborations

He collaborates with esteemed colleagues, including Mineo Tsuruda and Chiaki Kitami, to further enhance the impact of their research in the pharmaceutical field.

Conclusion

Shinro Setoguchi's contributions to pharmaceutical innovation are noteworthy, and his ongoing work continues to influence the industry positively. His dedication to developing new compounds showcases the importance of research and collaboration in advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…